UBS AM’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

UBS AM’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-51,000	Closed	-$4.97M	–	2751
2015 Q1	$4.97M	Buy	51,000 +3,400	+7%	+$360K	﹤0.01%	1048
2014 Q4	$4.42M	Sell	47,600 -100	-0.2%	-$7.89K	﹤0.01%	1067
2014 Q3	$3.28M	Sell	47,700 -2,200	-4%	-$158K	﹤0.01%	1138
2014 Q2	$5.23M	Sell	49,900 -4,809	-9%	-$409K	0.01%	1025
2014 Q1	$4.54M	Sell	54,709 -5,791	-10%	-$535K	﹤0.01%	1059
2013 Q4	$3.92M	Sell	60,500 -2,700	-4%	-$160K	﹤0.01%	1067
2013 Q3	$4M	Buy	63,200 +6,900	+12%	+$340K	﹤0.01%	1039
2013 Q2	$2.37M	Buy	+56,300	New	+$2.57M	﹤0.01%	1158

UBS AM's GEVA Position: Q2 2015 in Review

UBS AM sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 51,000 shares — an estimated $4.97M sold.

UBS AM first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $5.23M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

UBS AM reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
UBS AM sold 51,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $4.97M.
UBS AM first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
UBS AM's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $5.23M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on UBS AM's 13F filing for Q2 2015, filed 12 Aug 2015.